Physicians' Academy for Cardiovascular Education
Hyperkalemia is a major clinical problem. Prof. Stefan Anker talks about problems and risk associated with hyperkalemia.
In SwedeHF, a nationwide HF registry in Sweden, approximately 1 in 4 patients with HF were tested for iron deficiency (ID). ID was present in half of the tested population. 1 in 5 patients with ID received ferric carboxymaltose.
Low-dose rivaroxaban plus aspirin reduces ischemic limb and CV events in PAD patients after limb revascularization compared to aspirin alone, with consistent benefit in patients ≥75 years vs. <75 years. TIMI major bleedings were increased with rivaroxaban, regardless of age.
The FDA has granted Breakthrough Therapy Designation to empagliflozin as an investigational treatment for patients with HFpEF, following the results from the EMPEROR-Preserved trial.
Empagliflozin significantly reduced epicardial adipose tissue, subcutaneous adipose tissue, myocardial extracellular volume, matrix volume, cardiomyocyte volume, aortic stiffness and several inflammatory biomarkers, compared to placebo in nondiabetic patients with HFrEF.
ESC 2021 In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE) was compared to VKAs in elderly patients with AF who underwent TAVI.
The EAS FHSC have created a global registry of FH patients for the surveillance of FH worldwide. Findings of the present study on the adult population show that FH is diagnosed late and LDL-c targets are often not achieved.
What is Lp(a), how common are high Lp(a) levels and what is the relationship with CV events? Prof. Sattar answers these questions in a brief overview. With poll
An exploratory analysis of FOURIER showed that lowering of LDL-c by evolocumab below 40 mg/dL resulted in continued reduction of MACE in ASCVD patients.
ESC 2021 Which procedure is better when incidentally critical carotid artery stenosis is found; carotid surgery or stenting? Prof. Verheugt discusses findings of the ACST-2 trial.
The NHS has made an agreement on a population health management approach in those eligible for the PCSK9 siRNA inclisiran.
ESC 2021 The QUARTET trial showed that starting with a quarter-dose quadruple combination pill led to greater BP lowering compared to starting with standard dose monotherapy in patients with hypertension.
